Skip to Main Content

Paper Details

Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.
Cancer Res
25
2014
450,000 genome-wide CpGs, 6p21, CD8, CD8 T, CD8 T-cell, CpGs, EOC, HGS EOC, HLA-DMA, HLA-DOA, HLA-DQB1, HLA-DQB2, PSMB8, PSMB9, R class, TAP1, TTR, epithelial ovarian carcinoma, genes, high-grade serous (HGS) epithelial ovarian carcinomas, high-grade serous epithelial ovarian cancer, patient, patients, tumor, tumor mRNA, tumors
Author NameAffiliation
Chen WangMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Mine S CicekMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Sebastian M ArmasuMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Melissa C LarsonMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Gottfried E KonecnyMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Boris WinterhoffMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Jian-Bing FanMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Jian-Bing FanMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Marina BibikovaMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Marina BibikovaMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Brooke L FridleyMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
Ellen L GoodeMayo Clinic, David Geffen School of Medicine, University of California, University of Kansas Medical Center, Kansas and Vaccine and Gene Therapy Institute of Florida
  • 1 - 12

Datasets